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Abstract
Background: Previous quality of life (QoL) literature in bladder cancer (BC) patients has focused on finding the
preferred urinary diversion while little is known about the QoL of patients in medical oncological treatment (MOT). We
performed a systematic review to assess the existing literature on QoL in patients with muscle-invasive BC (MIBC)
undergoing MOT.
Methods: A systematic search of Pubmed and Embase was performed. Inclusion criteria were studies containing QoL
data for patients undergoing chemo- and/or radiotherapy. We extracted all QoL scorings at different time intervals and
on the six most prevalent domains: overall QoL, urinary, bowel sexual symptoms, pain and fatigue. The study was
carried out according to PRISMA guidelines for systematic reviews and GRADE was used to rate the quality of evidence
from the included studies.
Results: Of 208 papers reviewed, 21 papers were included. Twenty-one different QoL instruments were applied. The
only data on QoL during chemotherapy was from patients in clinical trials investigating new treatments. No
studies were found for patients in neoadjuvant treatment. The level of evidence at each time point was graded
as very low to moderate. From the studies included the overall QoL seemed inversely related to the organ-
specific impairment from sexual and urinary symptoms and increased with decreasing organ-specific symptoms
for long term survivors > 6 months after treatment.
Conclusions: Collection of data on QoL from patients with MIBC disease undergoing MOT has been sparse and
diverse. The present data can act as a summary but prompts for more prospective collection of QoL data from
BC patients.
Keywords: Bladder cancer, Chemotherapy, Muscle-invasive bladder cancer, Quality of life, Urothelial cancer
Background
Despite recent literature highlighting the evident benefit
of regular symptom reporting and early handling of side
effects by patient-reported outcomes, the implementa-
tion of such in daily practice has yet to occur [1–3]. For
patients receiving chemotherapy, clinical trials have trad-
itionally informed us about quality of life (QoL) for these
patients retrospectively as part of study reporting. These
reports, however, inform us about highly selected patient
populations eligible for enrollment in clinical trials, and
are often not containing cancer specific modules as
highlighted by three reviews in the field of bladder
cancer published 1999–2005 [4–6]. Thus, our knowledge
of QoL outside clinical trials remains sparse.
Bladder cancer (BC) patients are characterized by
heterogenic prognostics due to variation in their extent
of disease as illustrated by the division into non-muscle
invasive (NMIBC)/TaT1CIS, muscle invasive bladder
cancer (MIBC)/T2-T4 and metastatic BC. Great interest
and effort has been put into understanding health-re-
lated quality of life and symptomatic issues affecting the
overall QoL for MIBC patients having undergone surgi-
cal procedures [7, 8]. Little is to the authors’ knowledge* Correspondence: helle.pappot@regionh.dk1Department of Oncology, Rigshospitalet, Blegdamsvej 9, section 5073, 2100
Copenhagen Ø, Denmark
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Taarnhøj et al. Health and Quality of Life Outcomes           (2019) 17:20 
https://doi.org/10.1186/s12955-018-1077-6
known of the BC patients undergoing medical onco-
logical treatment.
As part of the planning of a randomized patient-reported
outcomes study in the BC population receiving medical
oncological treatment, we set out to review the current lit-
erature for BC patients receiving chemotherapy. The aim of
this study is to gather evidence of the QoL issues affecting
the lives of BC patients during all phases of their disease,
from diagnosis to treatment and thereafter thus informing
us of potential gaps in the literature. The results will fur-
thermore assist in determining which symptomatic
patient-reported outcomes to be used in a coming random-
ized trial. We therefore present a systematic review of the
QoL literature published on patients with locally advanced
or metastatic BC undergoing chemotherapy.
Methods
Search criteria
A systematic search was performed in PubMed using
the MeSH-terms ‘quality of life’, ‘urinary bladder neo-
plasms’, ‘drug therapy’ and included ‘quality of life’, ‘blad-
der cancer’ and ‘chemotherapy’ as title or abstract terms
(Additional file 1). The same search strategy was used in
Embase. A professional, full-time librarian assisted the
search to ensure systematics. The results were examined
by title (author GAT) and if found relevant abstract and
papers were read (GAT). Papers were found relevant if
they included quantitative QoL data from patients with
MIBC undergoing chemotherapy at any time point be-
fore, during or after their diagnosis or treatment. Radio-
therapy as treatment modality was included because no
papers with post-treatment QoL data were found for pa-
tients having undergone chemotherapy. To limit the
search to the relevant population the following exclusion
criteria were applied:
 not available in English
 published before 2000 thereby allowing for a slight
overlap with the previous reviews in order not to
dismiss valuable studies
 only comparing surgical procedures
 only involving NMIBC
 only abstract available.
Finally, to expand the results due to a modest number
of relevant studies, cross-references in the included
articles were examined. The search is graphically pre-
sented according to the PRISMA consort diagram (Fig. 1)
and was carried out according to the PRISMA guidelines
as a systematic review (Additional file 2) [9].
Data extraction and analysis
In order to construct graphs eliciting QoL over time, all
QoL measurements from the included papers (Table 1)
were noted. All scores on other scales than 0–100 were
converted to a 0–100 scale. Overall QoL is displayed
with values 0–100, with increasing scores illustrating a
better QoL, while the domain specific items are pre-
sented with a 0–100 scale, with an increasing score
implicating more impairment, displayed in Table 2 as
percentage impairment. The questionnaires with a re-
verse scaling of the domain specific items than de-
scribed above (the FACT-BL, the EPIC and the
domain-specific part of the SF-12), are scored on a
Likert-like scale with increasing scores representing
better QoL/fewer symptoms. These scorings were re-
verse transformed to represent percentage impairment
for comparability with the other studies. The
FACT-BL questionnaire scores comprise urinary,
bowel and sexual symptom distress in one score,
thereby disabling unique symptom scores for these
items. If no subgrouping into urinary, sexual and
bowel scores was specified for the studies applying
the FACT-BL, the FACT-BL scores were thus used in
Fig. 2 for the graphical presentation of urinary, bowel
and sexual symptoms, even though the FACT-BL
score then was used multiple times, thereby perhaps
over- or underestimating the given symptom. No
scores from patients having undergone primary surgi-
cal treatment (radical cystectomy) were included in
the analysis, thereby allowing summarized scores
without the known post-operative and instrumental
issues known to affect QoL influencing the results of
this review.
The GRADE criteria were applied for systematic
review of the studies included [10]. GRADE is a system
for assessing the quality of the evidence for the chosen
outcome. The chosen outcome in this review was the
determination of whether the sum of the studies in-
cluded at each time point could act as reliable evidence
for assessing QoL for the given population. Downg-
rading was considered based on either risk of bias,
inconsistency, indirectness, imprecision or apparent
publication bias. A risk of bias was assessed if the studies
included e.g. reported different outcomes, if the out-
comes from one study were diverging or low compliance
in the study introduced selection bias. Inconsistency was
determined if there was a large amount of clinical het-
erogeneity across the studies, participants or outcomes
or if the methods applied were different across studies.
Indirectness was determined if the population or out-
comes differed from the population or outcomes of
interest. Imprecision was established if the number of
patients included in the rating of the outcome was too
small to give a valid estimate of the outcomes. Publica-
tion bias was assessed by funnel plots looking at the pat-
tern of study results [10]. Reasons for each downgrading
assessment according to the categories above along with
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the findings of this analysis are given in Tables 3, 4, 5, 6
and the assessments reflect the degree of confidence we
can have of the summarized QoL scores described above.
The GRADE evaluation was done by two authors
(GAT, HP).
Ethical considerations
This study did not require national or institutional
approval.
Results
The search strategies in PubMed and Embase performed
2nd of July 2018, resulted in 103 and 105 scientific
papers, respectively. All 208 titles were examined and if
found relevant, abstracts and papers were read resulting
in eight eligible papers from PubMed and eleven eligible
paper from Embase. Four of these papers were overlap-
ping. Thus fifteen papers were reviewed for the purpose
of the study. Through cross-references a further six
papers were included, resulting in a total of 21 eligible
papers for review as illustrated in Fig. 1. The results are
listed by topic in Table 1.
Quality of life instruments
A total of 21 different QoL instruments were applied,
most frequently the EORTC QLQ-C30, SF-36, FACT-G
and FACT-BL, see Table 7, only displaying the validated
instruments (N = 18). BC specific items were used in
52% of the included papers, FACT-BL being the most
frequently used bladder specific measure. Five of the
studies used non-validated questionnaires, some as a
supplement to validated questionnaires, either developed
by the investigator or modified from other validated
questionnaires applied among other cancer groups, e.g.,
prostate cancer.
Main topics
All but two of the included studies defined the focus
areas as opposed to letting the patient define the areas
of most concern. The main focus areas listed in order
of declining frequency were global QoL (17/21, 81%),
urinary symptoms (12/21, 57%), bowel symptoms (12/
21, 57%), sexual function (10/21, 48%), fatigue (10/21,
48%), pain (8/21, 38%) and anxiety/depression (5/21,
24%). For the above listed focus areas, a graphical pres-
entation by disease phase is presented in Fig. 2.
Fig. 1 Flow chart in PRISMA consort diagram of the screening and selection of studies
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Anxiety/depression was not included in Fig. 2 because
of a limited number of studies with this focus. Other
focus areas were financial distress, nausea, dyspnea, in-
somnia, appetite loss, rash and neuropathy, but all were
only listed once.
The studies reporting global QoL all had subdivided
QoL into the following health related quality of life
domains: physical, mental, social, cognitive, emotional
and personal function.
Patients
Six of the 21 studies (29%) presented data from only
MIBC patients, whereas eight studies showed data from
both the NMIBC and MIBC populations. Four studies
presented QoL scores for patients with metastatic or
recurrent disease, two studies presented data for a mix of
MIBC and metastatic patients and one study reported
data on patients defined by the authors as ‘advanced’ BC
patients receiving chemotherapy, thereby potentially
including both patients undergoing neoadjuvant, curative
intended chemotherapy for locally advanced BC and
metastatic BC patients.
Treatment
One study collected QoL data before cystoscopy.
Thirteen of the 21 studies presented data from pa-
tients after receiving treatment, feasibly for compari-
son of two treatment modalities or to determine QoL
for long-term survivors. Only two of these studies col-
lected baseline data before treatment initiation. Seven
studies measured QoL from patients undergoing
chemotherapy, one of which was concurrent with
radiotherapy in a Phase 1 trial, three presenting data
from a Phase 2 trial and one from a Phase 3 trial.
None of these studies had QoL as the primary out-
come, and the Phase 1 trial was the only to include
bladder cancer specific items. A total of six of the 21
studies did not list the QoL scores or were not on a
Fig. 2 Summarized quality of life scores during disease phases for bladder cancer patients
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comparable scale and were therefore not included in
the analyses. The treatments consisted of combina-
tions of transurethral resection, radical cystectomy,
partial cystectomy,1 electrocoagulation, nephrour-
etherectomy, installation of Balcillus Calmette-Guérin
and radiotherapy with or without concurrent chemo-
therapy. There was a large disparity between the stud-
ies as one study had mainly surgically treated patients
in stages Ta-T1 and very few patients in need of
adjuvant treatment for more advanced stages while an-
other study presented patients volunteering for an in-
patient rehabilitation after their oncological treatment
suggesting more invasive treatment and sequelae
thereof.
Quality of life outcome
Two studies presented QoL before diagnosis as a
baseline QoL not affected by the distress and change
Table 4 GRADE Summary of findings. Outcome: Urinary symptoms
GRADE issues Overall GRADE rating
Nb. of studies Risk of bias Inconsistency Indirectness Imprecision Publication bias
Before diagnosis 2 [18, 27] X1 X2 X3
Before treatment 0 – – – – – N/A
During treatment 2 [16, 18] X4 X5 X3
≤ 6 months after treatment 2 [18, 27] X1 X3
> 6months after treatment 8 [20, 21, 23–27, 35] X6, X7 X8 X9 None apparent10
11 out of 2 scores from non-validated questionnaire [27]
2No studies before CT for metastatic disease or as neoadjuvant treatment
3Large difference in populations hence diverging scores
4Small number of patients
5Only one study representing metastatic population, no studies representing neoadjuvant population
6Diverging scores from one study [27]
7Small number of patients for [27] at time point 36 months
8Different incl. Non-validated questionnaires used
9All patients after CT/RT or RT alone
10As estimated by forest plot
Table 3 List of quality of life instruments applied, N=18
Abbreviated QoL
instrument
Full Title
EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of life Core Questionnaire – for all cancer
patients
EORTC QLQ-BLM30 European Organization for Research and Treatment of Cancer Quality of life module for muscle invasive bladder cancer
LENT-SOMA Late Effects in Normal Tissue – Subjective, Objective, Management and Analytic scale for late effects of radiotherapy
SF-36 RAND Medical Outcomes Study Short Form 36
SF-12 RAND Medical Outcomes Study Short Form-12
EPIC Expanded Prostate Cancer Index Composite
FACT-G Functional Assessment of Cancer Therapy – General – for all cancer patients
FACT-BL Functional Assessment of Cancer Therapy – for patients with bladder cancer
FACT-Taxane Functional Assessment of Cancer Therapy – for patients receiving taxane therapy
IPSS International Prostate Symptom Score
EuroQOL EQ-5D EuroQOL Group non-disease specific QoL instrument
CTPS Cancer Treatment Perception Scale
IOCv2 Impact of Cancer version 2
HADS Hospital Anxiety and Depression Scale
WHOQOL-BREF World Health Organization Quality of Life abbreviated version
STAI-10 State-Trait Anxiety Inventory-Trait scale short form
IIEF International Index of Erectile Function
Spitzer index Validated instrument for palliative patients
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of perspective of having a cancer diagnosis [11, 12].
Goossens-Laan et al. showed significantly poorer QoL
scores on erectile and orgasmic function in the BC
group vs. the group with hematuria from other causes
while Fung et al. displayed overall QoL data with a sig-
nificant fall in Physical and Mental Component Scores
(PCS, MCS) from pre- to post-diagnosis, although re-
sults were not clinically meaningful with small relative
differences in the two groups. For MIBC patients this
fall in PCS remained significant and clinically mean-
ingful for all times after diagnosis and was greatest for
patients with multiple comorbidities. This latter find-
ing was echoed by Perlis et al. for patients post treat-
ment [13].
When looking at QoL during treatment, the by far
largest study by von der Maase et al. (reported by
Roychowdhury et al.) with a total of 326 patients in two
treatment arms, reported improvement in QoL during
the chemotherapy treatment for metastatic patients.
However, the results were not found significantly differ-
ent from baseline values and no bladder specific items
were used [14, 15]. The studies by Joly, De Santis,
Herman and Albers all presented stable overall QoL
scores during chemotherapy treatment, although in the
Albers study this was, as for pain values, only seen for
responders [16–19]. Likewise, the study by Joly et al.
found an improvement in QoL among 10% of patients
with objective response or stabilization of disease as a
result of the treatment [16]. Herman et al. presented
significantly lower bladder specific scores for patients
receiving a higher dose of chemotherapy and lower
overall QoL scores for those experiencing dose-limiting
toxicities [18].
The QoL data from the after-treatment studies were
collected from 0 to 37 years after BC diagnosis and treat-
ment, rendering comparison somewhat difficult. How-
ever, for the patients having undergone radiotherapy as a
bladder conserving strategy, the majority of the studies
found the patients to have good or satisfactory bladder,
bowel and/or sexual function and superior to that of
cystectomy treated individuals when these were used as
control groups [20–25]. Nonetheless, Fokdal et al.
presented large impact on urinary, bowel and sexual
function and reported high prevalence of disturbances;
up to 94% impaired erective dysfunction while Lagrange
et al. presented deteriorating over time. Comparison was
Table 5 GRADE Summary of findings. Outcome: Sexual impairment
GRADE issues Overall GRADE rating
Nb. of studies Risk of bias Inconsistency Indirectness Imprecision Publication bias
Before diagnosis 1 [12] X1, X2 X3
Before treatment 1 [18] X1 X3
During treatment 2 [16, 18] X4 X5 X3
≤ 6 months after treatment 1 [18] X1 X3
> 6months after treatment 7 [20, 21, 23–26, 35] X6 None apparent7
1Only one study represented
2Selected population
3Small number of patients
4Large difference in populations hence diverging scores, despite same instrument used
5Only one study representing metastatic population, no studies representing neoadjuvant population
6Large range between scores despite comparable study populations, presumably due to different instruments used, incl. Non-validated instrument
7As estimated by funnel plo
vTable 6 GRADE Summary of findings. Outcome: Bowel symptoms
GRADE issues Overall GRADE rating
Nb. of studies Risk of bias Inconsistency Indirectness Imprecision Publication bias
Before diagnosis 0 – – – – – N/A
Before treatment 1 [18] X1 X2
During treatment 2 [16, 18] X3 X4 X2
≤ 6 months after treatment 1 [18] X1 X2
> 6months after treatment 7 [20, 21, 23–26, 35] X5 None apparent6
1Only one study represented
2Small number of patients
3Large difference in populations hence diverging scores, despite same instrument used
4Only one study representing metastatic population, no studies representing neoadjuvant population
5Large range between scores despite comparable study populations, presumably due to different instruments used, incl. Non-validated instruments
6As estimated by funnel plot
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in the Fokdal study made with population controls while
Lagrange presented data from only 6–7 individuals at
36 months [26, 27].
The QoL scores from the studies above are displayed
in Table 2 and gathered graphically in Fig. 2 displaying
the overall QoL and subdivisions into urinary, bowel and
sexual symptoms as well as pain and fatigue over the
time course of a MIBC patient’s treatment. The GRADE
evaluation was done for the overall QoL, urinary, sexual
and bowel symptoms but not conducted for the out-
comes fatigue and pain due to a very limited number of
studies rendering GRADE analysis redundant.
Overall, we found that QoL has been immensely ex-
plored for MIBC patients post-treatment, free of disease,
as shown by the GRADE analysis in Tables 3, 4, 5, 6. We
found no studies reporting data during treatment for
patients outside clinical trials, neither for the neoadju-
vant nor metastatic population. From the summarized
QoL scores in Fig. 2 it seems clear that especially urinary
symptoms and sexual impairment are important issues
for this group of patients. The GRADE analysis makes
clear that Fig. 2 should be interpreted with caution due
to the low level of evidence for almost all time-points.
Discussion
To the best of our knowledge, this review is the first to
compile quality of life studies in BC patients receiving
medical oncological treatment. We have portrayed a di-
versity in choice of QoL questionnaires and an absence
of studies informing us about QoL in the neoadjuvant
and metastatic populations outside clinical trials. The
summarized QoL curves in Fig. 2 lead us to believe that
urinary symptoms and sexual impairment impacts QoL
substantially due to their inverse relationship over the
course of time. The developmental curve of overall QoL
illustrates a tendency of increasing QoL after initiating
treatment followed by a fall in the early months after
treatment. Subsequently QoL increases in survivors
more than 6months after treatment. Also, only few
studies included psychological items in the QoL instru-
ments or as a supplement. However, a previous study
showed that bladder cancer diagnosis did not signifi-
cantly affect the patients’ levels of anxiety and depres-
sion [28], thus suggesting that QoL may not be
significantly influenced by these issues in bladder cancer
patients. Also, little attention has been paid to the psy-
chosocial issues of the patients and the importance of
these in relation to a person’s QoL, which ultimately
could explain the reported levels of QoL in the different
domains [29]. These issues are described in the literature
in the general cancer population [30–33]. From these
reports it is not evident in which direction psychosocial
difficulties interfere with a patient’s QoL as the studies
report diverging influences in the populations of interest,
thereby rendering a need to understand how QoL is
influenced by different psychosocial perspectives in the
BC population.
Based on this review one may question whether there
exists sufficient knowledge to reach the primary aim: to
understand the QoL of BC patients undergoing medical
Table 7 List of quality of life instruments applied, N = 18
Abbreviated QoL instrument Full Title
EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of life Core Questionnaire – for all cancer patients
EORTC QLQ-BLM30 European Organization for Research and Treatment of Cancer Quality of life module for muscle invasive bladder cancer
LENT-SOMA Late Effects in Normal Tissue – Subjective, Objective, Management and Analytic scale for late effects of radiotherapy
SF-36 RAND Medical Outcomes Study Short Form 36
SF-12 RAND Medical Outcomes Study Short Form-12
EPIC Expanded Prostate Cancer Index Composite
FACT-G Functional Assessment of Cancer Therapy – General – for all cancer patients
FACT-BL Functional Assessment of Cancer Therapy – for patients with bladder cancer
FACT-Taxane Functional Assessment of Cancer Therapy – for patients receiving taxane therapy
IPSS International Prostate Symptom Score
EuroQOL EQ-5D EuroQOL Group non-disease specific QoL instrument
CTPS Cancer Treatment Perception Scale
IOCv2 Impact of Cancer version 2
HADS Hospital Anxiety and Depression Scale
WHOQOL-BREF World Health Organization Quality of Life abbreviated version
STAI-10 State-Trait Anxiety Inventory-Trait scale short form
IIEF International Index of Erectile Function
Spitzer index Validated instrument for palliative patients
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oncological treatment. While the search string focused
on patients in chemotherapy, radiotherapy studies were
included because of the evident lack of post-treatment
studies informing us about the QoL after chemotherapy
treatment. The following apparent heterogeneity in con-
tent and design illustrated by the large variety of patients
comprising either BC patients only with hematuria [12],
recruited when in a clinical trial [14–16, 18, 19], recruited
in post-treatment clinic [34] or applying methodologically
problematic study designs challenging the implications of
results such as a cross-sectional setting [11], determining
QoL for patients having undergone radiotherapy without
applying radiotherapy-specific questionnaires [20, 21, 23,
26, 34] or recruiting patients years after diagnosis with no
baseline data [20, 21, 23–26, 35–38] renders careful
conclusions about the development of QoL through a
patient’s phases of disease.
Having addressed these issues, the most apparent
outlier in Fig. 2 deserves notice. The unmistakable and
permanent decrease in sexual impairment from before
cystoscopy to before treatment may be the parameter to
best distinguish MIBC patients in medical oncological
treatment from MIBC patients undergoing surgical
treatment. The latter are described as having a substan-
tial amount of sexual troubles after cystectomy, because
of the accompanying prostatectomy, a development not
described in this review [39, 40]. Sexual problems are
known to have a significant impact on QoL which makes
this development in Fig. 2 a paramount finding in this
review [41].
With the above issues in mind, this review is the first
to gather the raw data from previous studies and create
an overview of this diverse group of patients. Figure 2
may despite the apparent heterogeneity among the
studies serve as the currently best guidance for physi-
cians facing patients commencing medical oncological
treatment. When discussing worries about QoL as a
result of treatment, the results of this review may re-
assure patients unsure of future outcomes. Also, patients
unsure of the effects of urological surgical interventions
and searching for viable alternatives may need this
platform of evidence to assist treatment decisions.
Study limitations
Our attempt to align different QoL instruments and fur-
ther align various time points applied in different popu-
lations studied and assuming an equal weight of each
study presents a clear limitation of the present review.
The GRADE system, although systematic, does not take
into account the large cultural differences between two
otherwise comparable populations; a Japanese patient
may score QoL higher than an American patient despite
objectively the same burden of symptoms, or vice versa.
This may be the reason for the variation in scores as
listed in Table 2 and commented in Tables 3, 4, 5, 6.
Also, the combined scores of the FACT-BL instrument
may both over- and underestimate the impairment in
the urinary, bowel and sexual domains. The direction of
this estimate cannot be determined. These issues consti-
tute the need to interpret Fig. 2 with care, as illustrated
by the GRADE analysis. Further, for some of the time
points in this figure only one or two QoL scores make
up the supposed overview of QoL development, perhaps
falsely giving the single studies equal weight of time
points comprising many studies. Unfortunately, this is a
result of the scarce literature in this field and cannot be
avoided. The scares literature in certain populations or
time points may even give us valuable information of
which patient groups have not been studied as intensively
as others and guide us to future prospective research, in
this case towards an understanding of the QoL for BC pa-
tients in neoadjuvant chemotherapy and for the metastatic
population outside clinical trials. Lastly, although thor-
ough literature search was performed in the two chosen
databases including cross-references, the study group ac-
knowledges that a number of studies describing QoL in
advanced BC patients and specifically studies describing
QoL during or after radiotherapy may, because of our
chosen search string, not be included in our review. Also,
given the nature of the QoL outcome and the psycho-
logical construct related to overall QoL, the results may
have benefitted from a similar search in e.g. PsychInfo.
Conclusions
As set out to do, this review sheds new light on the
issues at hand for MIBC patients before, during and
after medical oncological treatment. It provides a listing
of QoL issues important for BC patients to include in
prospective patient-reported outcome trials and identi-
fies a need for further efforts to describe the QoL issues
with validated instruments for advanced and metastatic
BC patients, especially during treatment.
Endnote
1From Matsuda et al. [35] without further explanation.
May be cystectomy in women without resection of
internal genitalia.
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